行情

QURE

QURE

Uniqure
NASDAQ

实时行情|Nasdaq Last Sale

64.88
+2.17
+3.46%
已收盘, 16:00 02/19 EST
开盘
63.15
昨收
62.71
最高
65.88
最低
62.63
成交量
30.33万
成交额
--
52周最高
82.49
52周最低
36.20
市值
28.30亿
市盈率(TTM)
-23.7403
分时
5日
1月
3月
1年
5年

分析师评级

18位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

QURE 新闻

  • The Daily Biotech Pulse: Assertio To Sell Opioid Pain Drug, Milestone Payment For Aduro, Myriad Genetics CEO Resigns
  • Benzinga.02/07 13:27
  • uniQure Announces Presentations at the Upcoming 13th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD)
  • GlobeNewswire.02/04 12:00
  • Biotechs Feel The Bern
  • Seeking Alpha - Article.02/03 14:30
  • uniQure to Participate in Multiple Upcoming Industry Conferences in February
  • GlobeNewswire.01/31 12:00

更多

所属板块

生物技术和医学研究
+1.01%
制药与医学研究
+0.22%

热门股票

名称
价格
涨跌幅

QURE 简况

Uniqure NV is a company based in the Netherlands specialized in gene therapy. It seeks to develop one-time administered treatments with potentially curative results for patients suffering from genetic and other devastating diseases. It develops, both internally and through partnerships, a pipeline of gene therapies. It produces adeno-associated virus based, or AAV-based, gene therapies in its own facilities with a proprietary, commercial-scale, current good manufacturing practices, compliant, manufacturing process. AMT-061, the Company’s lead product candidate for patients with hemophilia B, is going through a dosing phase of a pivotal study. AMT-130, the product candidate for patients with Huntington’s disease is in Phase I/II clinical study.
展开

Webull提供Uniqure NV的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。